Mobile website
Archive > Volume 25 Issue 3 > 2018,25(3):213-220. DOI:10.3872/j.issn.1007-385X.2018.03.001 Prev Next
Expert Forum
Progress in clinical researches of immunotherapy for lung cancer targeting PD-1/PD-L1
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
The research on immune checkpoint has made breakthrough progress in recent years. The PD-1/PD-L1 signaling pathway is closely related to the immune escape mechanism, and their inhibitors have also made great success in lung cancer. From Checkmate- 017, Checkmate-057 to KEYNOTE-010 and OAK studies, PD-1/PD-L1 inhibitors have gradually established their position as standard treatment for the advanced NSCLC patients after chemotherapy failed. PD-1/PD-L1 inhibitors can be combined with other cancer treat- ment methods, including radiotherapy, chemotherapy, targeted therapy and other immunotherapies, whichhave synergistic effects in the treatment of lung cancer, thus improving the efficacy. Immune checkpoint inhibitors bring changes in the treatment patterns of lung can- cer, but also to the traditional efficacy evaluation model,as wellas reaction to the treatment-related adverse. In addition, the development of immune check point inhibitors has effectively promoted the progress of precision medicine.
Keywords:
Project Supported:
Project supported by the National Key Research and Development Program of China（Grant No.2016YFC1303800），the National Natural Science Foundation of China （No.81672275），the Key Laboratory Construction Project of Department of Science and Technology of Jilin Province（No. 20170622011JC），the Special Project of Development and Reform Commission in Jilin Province （No. 2017C022），and the Special Project of the National Health and Family Planning Commission of China （No. ZX-07-C2016004）
Clc Number:
